Literature DB >> 25077721

Common questions about late-term and postterm pregnancy.

Mary Wang1, Patricia Fontaine2.   

Abstract

Pregnancy is considered late term from 41 weeks, 0 days' to 41 weeks, 6 days' gestation, and postterm at 42 weeks' gestation. Early dating of the pregnancy is important for accurately determining when a pregnancy is late- or postterm, and first-trimester ultrasonography should be performed if clinical dating is uncertain. Optimal management of a low-risk, late-term pregnancy should consider maternal preference and balance the benefits and risks of induction vs. waiting for spontaneous labor. Compared with expectant management, induction at 41 weeks' gestation is associated with a small absolute decrease in perinatal mortality and decreases in other fetal and maternal risks without an increased risk of cesarean delivery. Although there is no clear evidence that antenatal testing beginning at 41 weeks' gestation prevents intrauterine fetal demise, it is often performed because the risks are low. When expectant management is chosen, most experts recommend beginning twice-weekly antenatal surveillance at 41 weeks with biophysical profile or nonstress testing plus amniotic fluid index (modified biophysical profile); induction may be deferred until 42 weeks if this surveillance is reassuring.

Entities:  

Mesh:

Year:  2014        PMID: 25077721

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  2 in total

1.  Induction of Labour in Late and Postterm Pregnancies and its Impact on Maternal and Neonatal Outcome.

Authors:  F Thangarajah; P Scheufen; V Kirn; P Mallmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-07       Impact factor: 2.915

2.  Association of Gestational Age at Birth With Subsequent Neurodevelopment in Early Childhood: A National Retrospective Cohort Study in China.

Authors:  Jing Hua; Anna L Barnett; Yao Lin; Hongyan Guan; Yuanjie Sun; Gareth J Williams; Yuxuan Fu; Yingchun Zhou; Wenchong Du
Journal:  Front Pediatr       Date:  2022-05-31       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.